People in the News
Exagen announced that it has appointed Ana Hooker to its board of directors. Hooker has been the SVP of operations at Exact Sciences since 2015 and joined the company in 2013 to open a new clinical laboratory. She was previously in multiple senior positions at ARUP Laboratories, including group manager for the divisions of oncology and genetics, VP decision manager for genetics, and SVP division manager for anatomic pathology, oncology, and genetics.
She is also a member of the Clinical Laboratory Management Association, Association of Molecular Pathology, and American Society of Clinical Laboratory Science.
Scott Gleason has joined OraSure Technologies as VP of investor relations and corporate communications. Previously, he was senior VP of investor relations and corporate strategy at Myriad Genetics, and before that, a senior publishing analyst at Stephens, covering the life science tools and diagnostics industry. Gleason holds a BS in economics from the US Air Force Academy in Colorado Springs.
Clinical diagnostics company Novacyt announced the appointment of David Allmond as CEO and a member of its board of directors, effective Oct. 18.
Allmond is chief business officer at Amryt Pharma, a rare and orphan disease drug company. He previously held sales and marketing roles at Amgen, Celgene, and Aegerion Pharmaceuticals.
Graham Mullis is retiring and will stand down as the company's CEO and board member.
Renalytix announced the appointment of Ann Berman to its board of directors. Berman will chair the board's audit committee and serve as a member of the nomination committee.
Berman currently serves on the board of directors and as a member of the audit committee of Loews, a $14.5 billion market capitalization company with subsidiaries that include CNA Financial. In addition, she is a member of the board of trustees of Beth Israel Deaconess Medical Center and Immuneering. Berman has also served as chief financial officer of Harvard University, where she was responsible for financial strategy, policy and planning, financial reporting and operations, treasury and risk management, and various audit functions.
Lucid Diagnostics, a majority-owned subsidiary of PAVMed, announced that Stanley Lupidis has joined the company as vice chairman of the firm's board of directors. Lupidis previously served as chairman and CEO of Exact Sciences, which he founded. He also founded and was president of Cytyc, a company focused on early cervical cancer detection. Previously, he served as cofounder, president, and CEO of SynapDx, an autism laboratory test company, and Helicos BioSciences, a DNA sequencing firm.
He is currently the chairman of the board of directors of Binx Health, Mirvie, Mercy Bioanalytics, and Droplet Biosciences. He's a member of the boards of Glympse Bio and PathAI. He also serves as an executive-in-residence at the University of Colorado Anschutz Medical Campus and a cofounding pillar at Pillar VC.
Centogene has appointed Patrice Denèfle as CSO, effective Aug. 16. He will succeed Phil Lambert, who decided to leave the company, which he joined in late 2019. Denèfle comes to Centogene from 4P-Pharma, where he was CSO. Prior to that, he was general manager of the Roche Institute for Research and Translational Medicine, and he held senior roles at Sanofi Aventis and Ipsen. He also served as CSO at rare disease biotech firm Genethon. Denèfle holds a PhD in molecular biology and biotechnology from the Pasteur Institute.
Babson Diagnostics has appointed Kristie Stanton VP of marketing, and Vicente Armendariz VP of strategy. Both appointments are effective immediately. Stanton was at CVS Health for more than a decade and most recently was the executive director of strategic marketing and digital engagement at Aetna. She also led the marketing department for CVS' MinuteClinic. Armendariz was most recently VP of corporate strategy at HMS, a provider of payment accuracy and population health management solutions. He also was at WellCare, CVS Health, and Humana.
CareDx has appointed Alex Johnson as its chief business officer and head of testing services.
Johnson has served as senior vice president of products, cell therapy and business development at CareDx since May 2020, and previously served as VP of the firm's laboratory solutions business from August 2018 to May 2020 and VP of finance from April 2018 to July 2018. Prior to joining the company, Johnson was chief operating officer of venture-backed immuno-oncology drug development company BioGraph 55, and served as president of Diadexus. He also worked at Novartis, with roles at Novartis Diagnostics and Novartis AG.
AnPac Bio-Medical Science, a cancer screening and detection company with operations in China and the US, has appointed Chao Feng as an independent director. He is succeeding Lin Yu, who resigned as a company director for personal reasons. Feng is the general manager of Shanghai Zhiruihaochen Information Technology. Previously, he was a key account project director at Hewlett Packard Enterprise China and a data discovery sales manager at Oracle China. He holds a bachelor's degree from Xidian University's School of Computer Science and Technology and an MBA from East China University of Science and Technology.
As part of its merger with special purpose acquisition company CM Life Sciences, Sema4 has appointed four new directors to its board: Eli Casdin, chief investment officer of Casdin Capital; Emily Leproust, CEO of Twist Bioscience; Jason Ryan, former chief operating officer and CFO of Magenta Therapeutics and former CFO of Foundation Medicine; and Nat Turner, cofounder of Flatiron Health.